NCT04148430
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
At risk: Primary completion moved at least 11 months later.
See at-risk trials from Memorial Sloan Kettering Cancer Center
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 15 versions: 10 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Oct 2026 to Oct 2027
- Eligibility criteria expanded, about 5 words
- Publications: details revised at 1 of 1 entry
- Notable Primary and study completion dates: Oct 2025 to Oct 2026v14
- Notable Primary and study completion dates: Oct 2024 to Oct 2025v12
- Notable Primary and study completion dates: Oct 2023 to Oct 2024
- Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 2 of 2 sites
- Minor Site details revised at 1 of 2 sitesv9
Show 4 earlier versionsHide 4 earlier versions
- Minor Study sites: 1 to 2v8
- Notable Enrollment target: 90 to 62
- Eligibility criteria shortened, about 263 words
- Study arms: 2 to 1
- Notable Primary and study completion dates: Oct 2022 to Oct 2023v4
- Notable Eligibility criteria expanded, about 272 words
- Primary endpoints: 1 to 2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Arm 1 (CAR T Cell Group) Rate of Severe Neurotoxicities
Timeframe: 4 weeks
Arm 2 (COVID-19 Group) proportion of patients able to avoid death or mechanical ventilation
Timeframe: 28 days from the start of treatment
Arms and interventions
Arm 1 (CART Cell Group)Experimental
Cohort 1 Patients will receive anakinra 100mg s.c. every 12 hours starting on day 2 post CAR T cell infusion, or after 2 documented fevers of ≥38.5° C prior to day 2, whichever time point is earlier. Anakinra will be continued for 10 days. Cohort 2 Patients will receive anakinra 100mg s.c. daily on day 0 of T cell infusion, and continue anakinra daily for 7 days
Drugs: Anakinra
Sites
2 sites in 1 country